多药耐药基因在乳腺癌组织中的表达及其与预后的关系

Expression of Multidrug Resistance Gene in Breast Carcinoma and Its Relationship with Prognosis

目的:研究P-gp、ToPoⅡ、GST-π在乳腺癌中的表达及与预后的关系。方法:乳腺癌标本78例行SP法免疫组化法染色。结果:P-gp阳性率为65.4%(51/78),Ⅲ期乳腺癌P-gp阳性率明显高于Ⅰ、Ⅱ期,P-gp阳性率与5年生存率呈负相关(P<0.05)。GST-π阳性表达率为70.5%(55/78),在乳腺癌临床Ⅲ期中其阳性表达率高达76.2%,与临床Ⅰ、Ⅱ期相比有显著性差异(P<0.05),其阳性表达率与5年生存率呈明显负相关(P<0.05)。ToPoⅡ的表达为64.1%(50/78),临床Ⅲ期表达明显低于Ⅰ,Ⅱ期。结论:化疗前检测P-gp,ToPoⅡ,GST-π的耐药基因蛋白,对判断乳腺癌的预后及指导化疗有一定的价值。

Objective：To explore expression of P-gp, ToPo Ⅱ , GST-π in breast carcinoma and its relationship with prognosis. Methods： Routine section preparation from 78 cases with breast cancer were measured with SP Immunohistochemistry method. Results：The positive rate of P-gp is 65.4% （51/78）and that in stage Ⅲ of breast carcinoma was obviously higher than that of stage Ⅰ and stage Ⅱ , the positive rate was negative correlation with 5-year survival rate（P〈0. 05）. The positive expression rate of GST-π was 70.5% （55/78）, that in clinical stage Ⅲ of breast carcinoma was up to 90.9% ,and there was significant difference among clinical stage Ⅲ and clinical stage Ⅱ , Ⅰ （P〈0. 05）,the positive expression rate was obviously negative correlation with 5- year survival rate（P〈0.05）. The positive expression rate of ToPo Ⅱ was 64.1% （50/78）, and that in clinical stage Ⅲ was obviously lower than stage I and stage Ⅱ. Conclusion： It is valuable to measure P-gp,ToPo Ⅱ, GST-π before chemotherapy for judging the prognosis of breast carcinoma and guiding the chemotherapy.